---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-24-000038"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:51:47.625727+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%

## Summary
- Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).
- Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.
- Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).
- FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.
- FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3.

## SEC filing metadata
- accession: 0001804220-24-000038
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/0001804220-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/regn-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-24-000038
- JSON: https://secwatch.observer/filing/0001804220-24-000038.json
- Plain text: https://secwatch.observer/filing/0001804220-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.